Kent Johnson, M.D.

Kent Johnson, M.D.
President

Dr. Johnson is an internationally recognized expert on inflammation and specifically diseases that are associated with inflammation and tissue injury. His research in this area has focused on the role of leukocytes in inflammation, their activation and the mediators produced by these cells. He has looked primarily at the inflammatory response in organs such as the lung, kidney and blood vessels. He has a long history of grant support in this area both in terms of NIH funding as well industry support from biotech and pharmaceutical companies such as Pfizer, Parke Davis, Genentech, Novartis, Benovus Bio and Medicis. He has over 200 peer review publications in this area.

Over the past few years Dr. Johnson has also concentrated on protein biomarker identification in the blood of patients with diseases such as kidney and vascular disease. Dr. Johnson has developed several animal models of lung, kidney and vascular injury and has identified several protein biomarkers that are present in the blood.

Clinically Dr. Johnson is a renal pathologist and in addition to clinical sign out activities works with the nephrologists and transplant surgeons in biomarker studies from patients with kidney disease and also in renal transplant patients. These studies have identified several proteins that are present in patients with kidney and vascular disease that can identify the type of disease process without having to do a tissue biopsy. These studies have resulted in several publications.

In addition Dr. Johnson has extensive collaborations with rheumatologists in the context of kidney injury in patients with autoimmune diseases such as lupus. Dr. Johnson works with these physicians in the protein biomarkers present in patients with vasculitis. These studies have been supported by many of the biotech and pharmaceutical companies listed above and have resulted in several publications including a recent publication of biomarkers present in a vasculitis consortium study.

Dr. Johnson has a long history of working as a consultant with biotech firms as well as drugs companies on preclinical drug development as well as in clinical studies. He has been on many drug development teams and also provides advice on clinical diseases such as kidney disease and vasculitis and has played a key role in the development and approval of many new drug candidates.

Dr. Johnson received his bachelor’s degree from the University of North Dakota in 1968. He received his M.D. from the University of Connecticut, School of Medicine, Farmington, CT in 1976. After a residency in Pathology (1977-1980) at the University of Connecticut, Dr. Johnson moved to the University of Michigan where he is a full professor in the Department of Pathology.